| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/17/2003 | WO2003057159A2 Psoriasin expression by breast epithelial cells |
| 07/17/2003 | WO2003057155A2 Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor |
| 07/17/2003 | WO2003057148A2 Use of biomolecular targets in the treatment and visualization of tumors |
| 07/17/2003 | WO2003057147A2 Useful aroyl pyrrole heteroaryl methanones and methanols |
| 07/17/2003 | WO2003057146A2 Novel compositions and methods for cancer |
| 07/17/2003 | WO2003057144A2 Change inhibitors of dipeptidyl peptidase iv |
| 07/17/2003 | WO2003057134A2 Specific binding agents of human angiopoietin-2 |
| 07/17/2003 | WO2003057130A2 Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof |
| 07/17/2003 | WO2003057012A2 S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer |
| 07/17/2003 | WO2003057007A2 System for monitoring bacterial tumor treatment |
| 07/17/2003 | WO2003057006A2 Use of antibodies against the muc18 antigen |
| 07/17/2003 | WO2003045907A3 Sir2 products and activities |
| 07/17/2003 | WO2003031595A3 Molecules for disease detection and treatment |
| 07/17/2003 | WO2003022252A3 Combinatorial type (several vehicles within a housing) controlled release drug delivery device |
| 07/17/2003 | WO2003020371A3 Potentiator composition comprising a terpene for enhancing a therapeutical effect of antitumoral agents in the treatment of cancer |
| 07/17/2003 | WO2003020325A3 Methods for sterilizing preparations containing albumin |
| 07/17/2003 | WO2003008573A3 Silencing of gene expression by sirna |
| 07/17/2003 | WO2003008410A3 Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression |
| 07/17/2003 | WO2003000896A3 POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-5 GENE |
| 07/17/2003 | WO2002099044A3 B3galts as modifiers of the p53 pathway and methods of use |
| 07/17/2003 | WO2002090566A3 Recombinant tumor specific antibody and use thereof |
| 07/17/2003 | WO2002083928A3 Nucleid acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer |
| 07/17/2003 | WO2002081646A3 Epitope sequences |
| 07/17/2003 | WO2002072008A3 Method for treating cancer using a33 specific antibodies and chemotherapeutic agents |
| 07/17/2003 | WO2002059286A3 Adenylate cyclases |
| 07/17/2003 | WO2002057450A3 Proteins and nucleic acids encoding same |
| 07/17/2003 | WO2002055693A3 Method for inhibiting the expression of a target gene |
| 07/17/2003 | WO2002046190A3 Sulfonamido ether substituted imidazoquinolines |
| 07/17/2003 | WO2002040683A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 07/17/2003 | WO2002039947A3 Carrier vectors through an epithelium with tight junctions |
| 07/17/2003 | WO2002038803A3 Novel marker for the diagnosis and therapy of tumours |
| 07/17/2003 | WO2002031134A3 Novel serine protease genes related to dppiv |
| 07/17/2003 | WO2002029060A9 Hematopoietin receptors hpr1 and hpr2 |
| 07/17/2003 | WO2002026998A3 Hydrolases |
| 07/17/2003 | WO2002022805A3 Modulation of il-2- and il-15-mediated t cell responses |
| 07/17/2003 | WO2002011759A9 Vaccines against cytokines and growth factors derived from malignant tumours |
| 07/17/2003 | WO2002011713A3 Methods of treating bone cancer and the pain associated therewith using endothelin antagonists |
| 07/17/2003 | US20030135053 For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics |
| 07/17/2003 | US20030135028 Human serine protease and serpin polypeptides |
| 07/17/2003 | US20030134901 Lipoxin compounds and their use in treating cell proliferative disorders |
| 07/17/2003 | US20030134899 Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect |
| 07/17/2003 | US20030134892 Compositions for treatment of head and neck cancers, and methods of making and using the same |
| 07/17/2003 | US20030134888 Substituted diaminopyrazoles; treating diseases, such as cancer, inflammatory disorders, restenosis, and cardiovascular disease. coatings for implantable medical devices, such as prostheses, artificial valves, etc. |
| 07/17/2003 | US20030134886 Pharmaceutically active compounds |
| 07/17/2003 | US20030134884 Benzyloxyiminohydrocarbylcarboxy compounds, such as E-4-(4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyloxyimino)--4-phenylbutyric acid |
| 07/17/2003 | US20030134883 Use in the treatment of cancer and other diseases characterized by undesired cellular hyperproliferation. |
| 07/17/2003 | US20030134859 Substituted 2-chloro-5-nitrobenzamides; treating retrograde osteoporosis and diabetes mellitus |
| 07/17/2003 | US20030134858 Treatment of inflammation associated disorders, such as arthritis, colon cancer, and Alzheimer's disease |
| 07/17/2003 | US20030134850 Hydrazinyl and nitrogen oxide pyrazoles |
| 07/17/2003 | US20030134849 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors |
| 07/17/2003 | US20030134847 New polycyclic azaindole compounds |
| 07/17/2003 | US20030134839 5-(Alkylidene-cycloalkyl)-and 5-(alkylidene-heterocyclyl)-pyrazoles |
| 07/17/2003 | US20030134837 Pharmaceutically acceptable salts thereof; their use as inhibitors of Raf kinases and pharmaceutical compositions containing them and anticancer agents |
| 07/17/2003 | US20030134836 Substituted arylamine derivatives and methods of use |
| 07/17/2003 | US20030134829 X is a ring having at least 4 atoms in the ring; K is hydrocarbyl group; Rh1 is an optional halo group; Rh2 is an optional halo group; at least one of Rh1 and Rh2 is present; Rs is any one of a sulphamate group, a phosphonate, |
| 07/17/2003 | US20030134810 Delivery of pharmacologically active agents associated with polymeric biocompatible materials. Compositions comprising a first, negatively charged pharmacologically active agent such as an oligonucleotide and a polycationic polymer such as |
| 07/17/2003 | US20030134800 Physiologically active substance in high content, suppressing the initial excess release, and achieving a stable release speed over a long period of time is provided. composition weight, (2) hydroxynaphthoic acid |
| 07/17/2003 | US20030134430 Novel amino acid sequences for human caenorhabditis elegans-like protein polypeptides |
| 07/17/2003 | US20030134390 An isolated polynucleotide molecule encoding an IL-21 antagonist polypeptide of specefic amino acid sequence; culturing |
| 07/17/2003 | US20030134350 Zinc finger domain recognition code and uses thereof |
| 07/17/2003 | US20030134344 Her2 gene amplification as detected by fluorescence in situ hybridization |
| 07/17/2003 | US20030134334 Use of vascular endothelial growth factor (VEGF) |
| 07/17/2003 | US20030134319 Amino acid sequences of peptides that are encoded by genes within the human genome, the kinase peptides |
| 07/17/2003 | US20030134315 Testing a sample from a cancer patient for the expression of a negative signal transduction factor (NSTF) and for the expression of a positive signal transduction factor (PSTF), selecting chemotherapeutic agent for treatment based on above |
| 07/17/2003 | US20030133988 Immunomodulation accomplished by administration of immunomodulatory polynucleotide/microcarrier complexes comprising 3-6 mer immunomodulatory oligonucleotides |
| 07/17/2003 | US20030133985 Controlled release oral dosage forms; data obtained using disintegration test such as the established USP Disintegration Test, rather than the results obtained using a standard USP Dissolution Test, as is conventionally done |
| 07/17/2003 | US20030133983 Comprises core and enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a derivative thereof; treatment of ulcerative colitis and Crohn's disease |
| 07/17/2003 | US20030133980 Biocompatible polymer blends and uses thereof |
| 07/17/2003 | US20030133973 Vesicle-forming lipid and a vesicle-forming lipid derivatized with a hydrophilic polymer |
| 07/17/2003 | US20030133964 Polymeric delivery formulations of leuprolide with improved efficacy |
| 07/17/2003 | US20030133954 Medical compositions for intravesical treatment of bladder cancer |
| 07/17/2003 | US20030133940 Medicaments for chemotherapeutic treatment of disease |
| 07/17/2003 | US20030133938 Antibody-avidin fusion proteins as cytotoxic drugs |
| 07/17/2003 | US20030133934 Method for enhancing the presentation of exogenous antigen by human antigen-presenting cells and opsonized micro particle complexes for applying this method |
| 07/17/2003 | US20030133930 Administering to a patient having an autoimmune disorder an antibody to a B-cell antigens and a carrier; CD22, CD20, CD19, and CD74 or HLA-DR antigen. |
| 07/17/2003 | US20030133913 Producing chemokine receptors, inducing antigen by dendritic cells in vitro, for therapeutic or prophylactic purposes |
| 07/17/2003 | US20030133911 Pneumovirus ns proteins antagonising the interferon (ifn) response |
| 07/17/2003 | US20030133910 Inhibiting cell proliferation by administering a large dosage of wild-type ras proteins |
| 07/17/2003 | US20030133909 An isolated polynucleotide encodes a polypeptide which comprising amino acids able to glycosylation, vaccines as an antitumor agent for treating mammal |
| 07/17/2003 | US20030133880 Powdery pharmaceutical compositions for inhalation |
| 07/17/2003 | US20030133872 Radiopharmaceutical agent for the treatment of early stage cancer |
| 07/17/2003 | US20030131532 Floral packaging material having great masters prints thereon |
| 07/17/2003 | CA2767061A1 Specific binding agents of human angiopoietin-2 |
| 07/17/2003 | CA2472893A1 Cancer treatment |
| 07/17/2003 | CA2472647A1 Mammal prolactin variants |
| 07/17/2003 | CA2472633A1 S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer |
| 07/17/2003 | CA2472585A1 Drug mixture with enhanced dissolution rate |
| 07/17/2003 | CA2472383A1 Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor |
| 07/17/2003 | CA2472282A1 Gene products differentially expressed in cancerous breast cells and their methods of use |
| 07/17/2003 | CA2472165A1 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists |
| 07/17/2003 | CA2472154A1 Use of antibodies against the muc18 antigen |
| 07/17/2003 | CA2472118A1 Pak5-related compositions and methods |
| 07/17/2003 | CA2472049A1 Dominant negative proteins and methods thereof |
| 07/17/2003 | CA2471957A1 Cyclic tetrapeptide compound and use thereof |
| 07/17/2003 | CA2471951A1 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 07/17/2003 | CA2471936A1 Methods for using anti-muc18 antibodies |
| 07/17/2003 | CA2471932A1 A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer |
| 07/17/2003 | CA2471868A1 Methods of generating multispecific, multivalent agents from vh and vl domains |
| 07/17/2003 | CA2471849A1 Antibodies against the muc18 antigen |
| 07/17/2003 | CA2471840A1 Novel compositions and methods for cancer |